KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Common Equity (2016 - 2025)

Charles River Laboratories International has reported Common Equity over the past 17 years, most recently at $3.2 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 8.72% year-over-year to $3.2 billion; the TTM value through Dec 2025 reached $3.2 billion, down 8.72%, while the annual FY2025 figure was $3.2 billion, 8.72% down from the prior year.
  • Common Equity for Q4 2025 was $3.2 billion at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
  • Over five years, Common Equity peaked at $3.8 billion in Q3 2024 and troughed at $2.2 billion in Q1 2021.
  • A 5-year average of $3.1 billion and a median of $3.2 billion in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: skyrocketed 32.25% in 2021 and later decreased 12.23% in 2025.
  • Year by year, Common Equity stood at $2.5 billion in 2021, then grew by 17.41% to $3.0 billion in 2022, then increased by 20.84% to $3.6 billion in 2023, then decreased by 3.76% to $3.5 billion in 2024, then dropped by 8.72% to $3.2 billion in 2025.
  • Business Quant data shows Common Equity for CRL at $3.2 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.4 billion in Q2 2025.